Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction

Cancer Immunology, Immunotherapy

Volumn 57, Issue 5, 2008, Pages 663-675

  Nechushtan, Hovav ^a,b   Pham, Dien ^a   Zhang, Yu ^a   Morgensztern, Daniel ^a   Yi, Kyung H ^a   Shin, Seung Uon ^a   Federoff, Howard J ^c   Bowers, William J ^c   Tolba, Khaled A ^a   Rosenblatt, Joseph D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESSENGER RNA; OVALBUMIN;

ADOPTIVE TRANSFER; AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; INNATE IMMUNITY; IRRADIATION; LYMPHOCYTE CULTURE; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; FLOW CYTOMETRY; GENES, VIRAL; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MICE; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMPLEXVIRUS; TRANSDUCTION, GENETIC;

EID: 43149098300     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0405-1     Document Type: Article

References (35)

1. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M (2003) Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 171:3941-3946
2. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ (2001) Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167:4878-4886
3. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854
4. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA et al (2005) Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357
5. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675
6. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345-352
7. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627-630
8. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH et al (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117:574-586
9. Goldrath AW, Bogatzki LY, Bevan MJ (2000) Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192:557-564
10. Ge Q, Hu H, Eisen HN, Chen J (2002) Naive to memory T-cell differentiation during homeostasis-driven proliferation. Microbes Infect 4:555-558
11. Goldrath AW, Luckey CJ, Park R, Benoist C, Mathis D (2004) The molecular program induced in T cells undergoing homeostatic proliferation. Proc Natl Acad Sci USA 101:16885-16890
12. Tanchot C, Le Campion A, Martin B, Leaument S, Dautigny N, Lucas B (2002) Conversion of naive T cells to a memory-like phenotype in lymphopenic hosts is not related to a homeostatic mechanism that fills the peripheral naive T cell pool. J Immunol 168:5042-5046
13. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, Chang AE (2003) Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63:8466-8475
14. Cao ZA, Daniel D, Hanahan D (2002) Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11
15. Maine GN, Mule JJ (2002) Making room for T cells. J Clin Invest 110:157-159
16. Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99:931-936
17. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN (2002) T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110:185-192
18. Hu HM, Poehlein CH, Urba WJ, Fox BA (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62:3914-3919
19. Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu HM (2003) Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 33:2123-2132
20. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76:17-27
21. Ikawa M, Yamada S, Nakanishi T, Okabe M (1998) 'Green mice' and their potential usage in biological research. FEBS Lett 430:83-87
22. Geller AI, Freese A (1990) Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase. Proc Natl Acad Sci USA 87:1149-1153
23. Bowers WJ, Olschowka JA, Federoff HJ (2003) Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther 10:941-945
24. Dhanji S, Teh SJ, Oble D, Priatel JJ, Teh HS (2004) Self-reactive memory-phenotype CD8 T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell receptor and natural killer cell receptors. Blood 104:2116-2123
25. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN (2006) A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107:935-944
26. Strbo N, Oizumi S, Sotosek-Tokmadzic V, Podack ER (2003) Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity 18:381-390
27. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29:3295-3301
28. Kutubuddin M, Federoff HJ, Challita-Eid PM, Halterman M, Day B, Atkinson M, Planelles V, Rosenblatt JD (1999) Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93:643-654
29. Tolba KA, Bowers WJ, Muller J, Housekneckt V, Giuliano RE, Federoff HJ, Rosenblatt JD (2002) Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res 62:6545-6551
30. Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW (2004) The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 173:1738-1743
31. Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ (2001) Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 166:1097-1105
32. Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197:1141-1151
33. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF (1999) Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 162:3256-3262
34. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174:4465-4469
35. CpG 7909: PF 3512676, PF-3512676. Drugs 2006 R D, 7:312-316